LONDON, UK, 18 July 2013 – Optos plc (LSE: OPTS), the leading medical retinal imaging company, today publishes its Interim Management Statement for the period from 1st October 2012 to today, including data for the third quarter of its financial year ending 30 September 2013 (Q313) and nine months to 30 June 2013 (YTD13). All figures are reported in US$ and are unaudited.
Today we report Q313 headline revenues of $40.1m, marginally lower than the comparable period last year (Q312: $40.9m), however, underlying1 revenue for the quarter grew 14% driven by outright ("capital") sales in our direct markets. With the traditionally strong Q4 ahead of us and strong momentum from Daytona installations, we remain on track to meet the market's revenue expectations for the full year.
Roy Davis, CEO, commented:
"We continue to see significant growth in new customers which has translated into a 16% increase in our installed base. We believe this reflects strong demand for our unique ultra-wide field capabilities. In particular, we are pleased with Daytona's performance with 323 units installed in Q3. Customer feedback is positive and our order book continues to grow. With our traditionally strongest quarter ahead of us and good progress with Daytona installations, we remain on track to deliver against the market's revenue expectations for the full year."
1. Underlying revenue growth is calculated by treating all payments receivable in the period from rental contracts as if they were operating leases, regardless of the actual accounting treatment, together with revenues from outright device sales and service contracts
Roy Davis, CEO
Louisa Burdett, CFO
|Tel: 01383 843 300|
Ben Atwell / Simon Conway / Mo Noonan
|Tel: 020 7831 3113|
Note to Editors: Images available upon request